Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles.

Su X, Yang N, Wittrup KD, Irvine DJ.

Biomacromolecules. 2013 Apr 8;14(4):1093-102. doi: 10.1021/bm3019906. Epub 2013 Mar 11.

2.

Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity.

Shin MC, Min KA, Cheong H, Moon C, Huang Y, He H, Yang VC.

Pharm Res. 2016 Sep;33(9):2218-2228. doi: 10.1007/s11095-016-1959-4. Epub 2016 Jun 1.

3.

Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin.

Provoda CJ, Stier EM, Lee KD.

J Biol Chem. 2003 Sep 12;278(37):35102-8. Epub 2003 Jun 27.

4.

Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.

Shin MC, Zhang J, Ah Min K, Lee K, Moon C, Balthasar JP, Yang VC.

J Control Release. 2014 Nov 28;194:197-210. doi: 10.1016/j.jconrel.2014.08.030. Epub 2014 Sep 7.

5.

Intracellular Protein Delivery System Using a Target-Specific Repebody and Translocation Domain of Bacterial Exotoxin.

Kim HY, Kang JA, Ryou JH, Lee GH, Choi DS, Lee DE, Kim HS.

ACS Chem Biol. 2017 Nov 17;12(11):2891-2897. doi: 10.1021/acschembio.7b00562. Epub 2017 Oct 25.

PMID:
29019389
6.

Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin.

Pirie CM, Liu DV, Wittrup KD.

Mol Cancer Ther. 2013 Sep;12(9):1774-82. doi: 10.1158/1535-7163.MCT-12-1023. Epub 2013 Jul 5.

7.

Molecular tumor targeting of gelonin by fusion with F3 peptide.

Ham SH, Min KA, Shin MC.

Acta Pharmacol Sin. 2017 Jun;38(6):897-906. doi: 10.1038/aps.2017.20. Epub 2017 Apr 17.

PMID:
28414205
8.

Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment.

Shin MC, Min KA, Cheong H, Moon C, Huang Y, He H, Yang VC.

Int J Pharm. 2017 May 30;524(1-2):101-110. doi: 10.1016/j.ijpharm.2017.03.072. Epub 2017 Mar 27.

PMID:
28359823
9.

Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.

Shin MC, Zhang J, David AE, Trommer WE, Kwon YM, Min KA, Kim JH, Yang VC.

J Control Release. 2013 Nov 28;172(1):169-78. doi: 10.1016/j.jconrel.2013.08.016. Epub 2013 Aug 23.

10.

Saponins modulate the intracellular trafficking of protein toxins.

Weng A, Thakur M, von Mallinckrodt B, Beceren-Braun F, Gilabert-Oriol R, Wiesner B, Eichhorst J, Böttger S, Melzig MF, Fuchs H.

J Control Release. 2012 Nov 28;164(1):74-86. doi: 10.1016/j.jconrel.2012.10.002. Epub 2012 Oct 10.

PMID:
23063550
11.

Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter.

Wang Z, Zhou X, Li J, Liu X, Chen Z, Shen G, Guan T, Ye N, Wei X, Huang N, Yang L, Wei Y, Li J.

Neoplasma. 2013;60(5):469-79. doi: 10.4149/neo_2013_061.

PMID:
23790164
12.

Toxin-targeted design for anticancer therapy. II: Preparation and biological comparison of different chemically linked gelonin-antibody conjugates.

Delprino L, Giacomotti M, Dosio F, Brusa P, Ceruti M, Grosa G, Cattel L.

J Pharm Sci. 1993 Jul;82(7):699-704.

PMID:
8360843
13.

Photochemical disruption of endocytic vesicles before delivery of drugs: a new strategy for cancer therapy.

Prasmickaite L, Høgset A, Selbo PK, Engesaeter BØ, Hellum M, Berg K.

Br J Cancer. 2002 Feb 12;86(4):652-7.

14.

In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy.

Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K.

Int J Cancer. 2001 Jun 1;92(5):761-6.

15.

15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.

Ye J, Shin MC, Liang Q, He H, Yang VC.

J Control Release. 2015 May 10;205:58-69. doi: 10.1016/j.jconrel.2014.12.002. Epub 2014 Dec 4. Review.

PMID:
25483423
16.

Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin.

Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K.

Int J Cancer. 2000 Sep 15;87(6):853-9.

17.

Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.

Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, Murray JL.

Cancer Immunol Immunother. 1996 Feb;42(2):115-21.

PMID:
8620520
18.

Aptamer:toxin conjugates that specifically target prostate tumor cells.

Chu TC, Marks JW 3rd, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M.

Cancer Res. 2006 Jun 15;66(12):5989-92.

19.

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG.

Mol Cancer Ther. 2012 Jan;11(1):143-53. doi: 10.1158/1535-7163.MCT-11-0519. Epub 2011 Nov 16.

20.

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Pérez-Herrero E, Fernández-Medarde A.

Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Review.

Supplemental Content

Support Center